枸橼酸铋钾、克拉霉素和替硝唑治疗慢性胃炎的胃窦粘膜病理学改变

目的 :观察枸橼酸铋钾、克拉霉素和替硝唑三联治疗幽门螺杆菌相关性胃炎胃窦粘膜组织病理学改变。方法 :38例幽门螺杆菌 (Hp)感染的慢性胃炎病人按就诊前后入选 ,分为 2组 ,枸橼酸铋钾三联 (BCT)组和奥美拉唑三联 (OCT)组 ,分别给予口服枸橼酸铋钾 +克拉霉素 +替硝唑和奥美拉唑 +克拉霉素 +替硝唑 ,治疗 1wk。 4wk后检查13 C 尿素呼气试验 ,8mo后复查胃镜和胃粘膜活检。结果 :BCT组Hp根除率为 80 % ,OCT组为 83% ,2组间差异无显著意义 (P >0 .0 5 )。 2组病人治疗后胃粘膜组织慢性炎症、活动性炎症明显减轻 (P <0 .0 5 ) ,粘膜萎缩及肠化生程度无明显变化 (P >0 .0 5 )。BCT组与OCT组间病理学改变差异无显著意义 (P >0 .0 5 )。结论 :幽门螺杆菌感染与胃粘膜炎症反应有关 ,BCT具有较高的幽门螺杆菌根除率 ,并可减轻胃粘膜的炎症反应

Pathological changes of gastric mucosa in Helicobacter pylori infected chronic gastritis treated with bismuth potassium citrate, clarithromycin and tinidazole

AIM: To investigate the pathological changes of gastric mucosa of Helicobacter pylori(Hp) gastritis in the triad treatment of with bismuth potassium citrate, charithromyein and tinidazole(BCT). METHODS: Thirty eight Hp infected chronic gastritis patients were divided into BCT group(bismuth potassium citrate 220 mg, clarithromycin 250 mg, tinidazole 500 mg, bid) and OCT group(omeprazole 20 mg, clarithromycin 250 mg and tinidazole 500 mg, bid). After 4 wk 13 C urease breath test was taken, endoscopy and biopsy were taken after 8 mo. RESULTS: The Hp eradication rate of BCT and OCT was 80 %,83 %, respectively. There were obviously ameliorated in the active inflammation and chronic inflammation( P <0.05), but degree of atrophy and intestinal metaplasia was not significontly changed( P >0.05). CONCLUSION: Hp infection is closely related with inflammation of gastric mucosa. BCT triad treatment has high rate of Hp eradication and is beneficial for the improvement of chronic inflammation of gastric mucosa.